T Cell News and Research

Latest T Cell News and Research

Bone marrow stem cells offer potential treatment for patients with peripheral arterial disease

Bone marrow stem cells suspended in X-ray-visible microbubbles dramatically improve the body's ability to build new blood vessels in the upper leg-providing a potential future treatment for those with peripheral arterial disease or PAD, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

18 Mar 2010

LSUHSC: Differences in drug metabolism can lead to differences in the effectiveness of candidate drug

Research led by Wayne L. Backes, PhD, Professor of Pharmacology and Associate Dean for Research at LSU Health Sciences Center New Orleans School of Medicine, has found that drug metabolism depends not only upon which enzymes are present in an individual, but also how they interact, and that can be the difference in whether a drug is safely eliminated from the body or is converted into a toxic or carcinogenic byproduct.

18 Mar 2010

SBRT can improve survival rates for patients with inoperable non-small cell lung cancer

Highly-focused stereotactic body radiation therapy (SBRT) can eliminate the targeted tumor while avoiding treatment-related illness and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to early findings of a Radiation Therapy Oncology Group study published in the March 17 cancer-themed issue of the Journal of the American Medical Association.

18 Mar 2010

SBRT doubles rate of primary tumor control compared to conventional radiotherapy

Early findings suggest a radiation therapy that involves numerous highly-focused and potent radiation beams provides targeted tumor control in nearly all patients, reduces treatment-related illness, and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to a study in the March 17 issue of JAMA, a theme issue on cancer.

18 Mar 2010

Toxins released by certain microalgae can contaminate seafood and become toxic to humans

Toxins released by certain microalgae can contaminate fish and shellfish which then become toxic to humans. Researchers from CNRS and CEA have, for the first time, identified the mechanisms of action of two of these toxins.

18 Mar 2010

Scientists discover switch mechanism that controls cells' trafficking system

Scientists have identified a mechanism that switches on an extremely important process for the proper functioning and survival of our body's cells. Specifically, the fast-track transportation pathway of 'cargo' to and from the surface of the cell.

18 Mar 2010

Grass-roots initiative raises more than $20 million to advance MDA's lifesaving mission

The spirit of St. Patrick's Day is alive and well. The Muscular Dystrophy Association today announced that, with 92 percent of some 10,000 retail locations reporting, its 2010 Shamrocks Against Dystrophy fundraiser is the most successful in the event's 27 year history.

18 Mar 2010

Research shows Caspase-1 protein plays a key role in the process of inflammation and colon cancer

Every day, our gut comes in contact with bacteria, inducing an inflammatory response that is tolerated and controlled. Sometimes the control of inflammation is lost and this can lead to inflammatory bowel disease that may predispose to colon cancer.

18 Mar 2010

Novel findings point to new therapeutic approaches for common types of cancer

Increased understanding of the Skp2 gene and its relation to cellular senescence may lead to the development of novel agents that can suppress tumor development in common types of cancer, researchers from The University of Texas M. D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center report in the journal Nature.

18 Mar 2010

New findings promise to have fundamental significance in the fight against cancer

Cells have two different protection programs to safeguard them from getting out of control under stress and from dividing without stopping and developing cancer. Until now, researchers assumed that these protective systems were prompted separately from each other.

18 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company’s proprietary intellectual property for ICT-109 and ICT-37, two of the Company’s monoclonal antibody product candidates.

17 Mar 2010

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

17 Mar 2010

SBRT improves survival in patients with inoperable non-small cell lung cancer

17 Mar 2010

SBRT may improve survival rates for lung-cancer patients: Study

A radiation therapy that uses multiple radiation beams to target tumors precisely has been shown to eliminate the primary tumor and ultimately may improve survival rates for lung-cancer patients unable to undergo surgery, according to UT Southwestern Medical Center physicians who led a national clinical trial of the treatment.

17 Mar 2010

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Protalix BioTherapeutics, Inc. announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated recombinant human acetylcholinesterase product candidate in development for biodefense indications. The trial is designed to study the safety of PRX-105 by administering a bolus intravenous injection of PRX-105 in healthy volunteers.

17 Mar 2010

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

17 Mar 2010

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

An interventional radiology treatment-the use of intra-arterial yttrium-90 microspheres for liver cancer (also known as hepatocellular carcinoma)-shows promise in prolonging life for many patients with this devastating condition, according to researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

Ingenuity Systems selects Biodiagnostics as new distributor of IPA in Greece, Turkey and Balkan countries

Ingenuity Systems, the leading provider of information solutions for life science researchers, has selected Biodiagnostics as its new distributor of IPA® in Greece, Turkey and the Balkan countries. IPA is the leading software application to model, analyze, and understand the complex biological and chemical systems at the core of life science research.

17 Mar 2010

BeaconEquity.com: CTIC' total net operating expenses for fourth-quarter of 2009 are $26.2M

BeaconEquity.com announces an investment report featuring Cell Therapeutics Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

17 Mar 2010

Cord Blood America produces new edition of Corporate Profile

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ), focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced its has produced a new edition of Corporate Profile, which is used to answer inquiries about the Company from brokers, investors and other interested individuals.

17 Mar 2010

T Cell News and Research

Latest T Cell News and Research

Bone marrow stem cells offer potential treatment for patients with peripheral arterial disease

LSUHSC: Differences in drug metabolism can lead to differences in the effectiveness of candidate drug

SBRT can improve survival rates for patients with inoperable non-small cell lung cancer

SBRT doubles rate of primary tumor control compared to conventional radiotherapy

Toxins released by certain microalgae can contaminate seafood and become toxic to humans

Scientists discover switch mechanism that controls cells' trafficking system

Grass-roots initiative raises more than $20 million to advance MDA's lifesaving mission

Research shows Caspase-1 protein plays a key role in the process of inflammation and colon cancer

Novel findings point to new therapeutic approaches for common types of cancer

New findings promise to have fundamental significance in the fight against cancer

ImmunoCellular Therapeutics receives Notice of Allowance covering antibodies targeting pancreatic cancer

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

SBRT improves survival in patients with inoperable non-small cell lung cancer

SBRT may improve survival rates for lung-cancer patients: Study

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

Ingenuity Systems selects Biodiagnostics as new distributor of IPA in Greece, Turkey and Balkan countries

BeaconEquity.com: CTIC' total net operating expenses for fourth-quarter of 2009 are $26.2M

Cord Blood America produces new edition of Corporate Profile

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in